



Universiteit
Leiden
The Netherlands

Preclinical evaluation of anti-restenotic therapies and drug-eluting stents : efficacy and safety considerations

Pires, Nuno Miguel Marques

Citation

Pires, N. M. M. (2007, March 22). *Preclinical evaluation of anti-restenotic therapies and drug-eluting stents : efficacy and safety considerations*. Department of Cardiology, Faculty of Medicine / Leiden University Medical Center (LUMC), Leiden University. Retrieved from <https://hdl.handle.net/1887/11455>

Version: Not Applicable (or Unknown)

License:

Downloaded from: <https://hdl.handle.net/1887/11455>

Note: To cite this publication please use the final published version (if applicable).

Stellingen behorend bij het profschrift

Preclinical evaluation of anti-restenotic therapies and drug-eluting stents Efficacy and safety considerations

1. Sirolimus and paclitaxel: similar anti-restenotic efficacy but different safety profile. (This thesis)
2. Side effects of anti-restenotic compounds are more important for their ultimate successful implication in clinical practice than their efficacy. (This thesis)
3. TNF α is a pro-inflammatory factor with pro-restenotic effects. Blocking TNF α holds a lot of potential as an anti-restenotic strategy. (This thesis)
4. The nuclear orphan receptor Nur77 is not an orphan anymore. (This thesis)
5. It is not justified to evaluate anti-restenotic compounds solely on their direct effect on restenosis, since these compounds are applied via drug-eluting stents to vascular lesions with a complex atherosclerotic pathology. Anti-restenotic therapies must be evaluated on both their efficacy and safety profile. (This thesis)
6. Combination of preclinical and clinical research is a strong step forward for the acceptance of an experimental hypothesis. (This thesis)
7. The knowledge that atherosclerosis is an inflammatory disease offers new opportunities for the prevention and treatment of coronary artery disease. Powerful immunosuppressant or anti-inflammatory agents could represent attractive treatments for acute coronary syndromes. (Hansson GK. N Engl J Med. 2005;352:1685-95)
8. The future for controlling coronary artery disease looks bright. Progress will not stop here. (King SB 3rd. Circulation 2003;108:248-249)
9. Drug-eluting stents are not a panacea as suggested by many interventional cardiologists. (Virmani R et al. Coron Artery Dis 2004;15:313-318)
10. Copy from one, it's plagiarism; copy from two, it's research. (Wilson Mizner)
11. Truth in science can be defined as the working hypothesis best suited to open the way to the next better one. (Konrad Z. Lorenz)
12. A PhD project is an exponential learning curve.
13. Portugal and Holland should meet more often; both of us have things to teach and learn from each other.

Nuno Pires
22 maart 2007